lestaurtinib has been researched along with incb-018424 in 7 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (incb-018424) | Trials (incb-018424) | Recent Studies (post-2010) (incb-018424) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 1,487 | 185 | 1,451 |
| Protein | Taxonomy | lestaurtinib (IC50) | incb-018424 (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.12 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0573 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0001 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0327 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0962 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3547 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Verstovsek, S | 1 |
| Geyer, HL; Mesa, RA; Tibes, R | 1 |
| Benson, KL; Bogenberger, JM; Mesa, RA; Tibes, R | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
3 review(s) available for lestaurtinib and incb-018424
| Article | Year |
|---|---|
Therapeutic potential of JAK2 inhibitors.
Topics: Animals; Carbazoles; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Furans; Humans; Janus Kinase 2; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Point Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidines; Signal Transduction; Splenomegaly; Sulfonamides; Weight Gain | 2009 |
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Benzamides; Bridged-Ring Compounds; Carbazoles; Chromatin; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Furans; Gene Expression Regulation; Humans; Ikaros Transcription Factor; Intracellular Signaling Peptides and Proteins; Isocitrate Dehydrogenase; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Polycomb Repressive Complex 2; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Pyrazoles; Pyrimidines; Pyrrolidines; Receptors, Thrombopoietin; Repressor Proteins; Signal Transduction; Spliceosomes; Sulfonamides | 2012 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
4 other study(ies) available for lestaurtinib and incb-018424
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Topics: Animals; Benzamides; Bridged-Ring Compounds; Carbazoles; Furans; Humans; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidines; Sulfonamides | 2012 |